ライフサイエンスコーパス: blood pressure control

1 of early treatment for SCI for all cases was blood pressure control.

2 nucleus (PVN), a key central coordinator of blood pressure control.

3 eration, angiogenesis, channel activity, and blood pressure control.

4 benefit from late CNI withdrawal by improved blood pressure control.

5 e to osmotic stress is important to systemic blood pressure control.

6 sels and is considered a major mechanism for blood pressure control.

7 (ENaC) is critical for Na(+) homeostasis and blood pressure control.

8 LV diastolic function and facilitated better blood pressure control.

9 ignificantly differ between strict and usual blood pressure control.

10 bitors and beta-blockers, and low for strict blood pressure control.

11 ial Na(+) absorption, a major contributor to blood pressure control.

12 ing bilateral adrenalectomy in childhood for blood pressure control.

13 ertensives may facilitate efforts to improve blood pressure control.

14 Renin is essential for blood pressure control.

15 gic system in salt and water homeostasis and blood pressure control.

16 rminalis), thereby evaluating their roles in blood pressure control.

17 i-ischemic therapy, and aggressive lipid and blood pressure control.

18 l ENaC is critical for Na(+) homeostasis and blood pressure control.

19 nal C1 adrenergic neurons and is involved in blood pressure control.

20 echanism by which patient education improved blood pressure control.

21 ivate patients to achieve strict glucose and blood pressure control.

22 uation of the hypertensive patient with poor blood pressure control.

23 dication when evaluating a patient with poor blood pressure control.

24 are had room for improvement, especially for blood pressure control.

25 sport, contributing to Na(+) homeostasis and blood pressure control.

26 tment with more than 1 drug class to achieve blood pressure control.

27 overt CHF who are candidates for aggressive blood pressure control.

28 effective as enalapril in LVH regression and blood pressure control.

29 fering is an important mechanism in arterial blood pressure control.

30 ose associated with conventional therapy and blood pressure control.

31 plays a critical role in Na+ homeostasis and blood pressure control.

32 nd tubular function that, in turn, influence blood pressure control.

33 n-angiotensin system, a major participant in blood pressure control.

34 ve treatment still remain on medications for blood pressure control.

35 d felodipine, a calcium channel blocker, for blood pressure control.

36 s also received furosemide concomitantly for blood pressure control.

37 or insulin resistance, lipid metabolism, and blood pressure control.

38 lead to significantly improved clinic-based blood pressure control.

39 al therapy to achieve optimal heart rate and blood pressure control.

40 s with hypertension fail to achieve adequate blood pressure control.

41 management processes needed to attain >=80% blood pressure control.

42 rations in microbial communities relevant in blood pressure control.

43 These factors are associated with poor blood pressure control.

44 n important role in fluid volume balance and blood pressure control.

45 ent reviews for people with poor glycemic or blood pressure control.

46 f adherence to antihypertensive treatment on blood pressure control.

47 can prevent glucose intolerance and improve blood pressure control.

48 equired for physiological vasoreactivity and blood pressure control.

49 nal inflammation and fibrosis independent of blood pressure control.

50 ease to receive either intensive or standard blood-pressure control.

51 nts usually need two or more medications for blood-pressure control.

52 her risk of coronary events, despite similar blood-pressure control.

53 e and 60% of treated hypertensive people had blood pressure controlled.

54 with antihypertensive medications have their blood pressure controlled.

55 uestion in hypertension is: How is long-term blood pressure controlled?

56 (1.26, 1.08-1.47; p=0.0038), and have their blood pressure controlled (1.13, 1.00-1.28; p=0.0562) th

57 ed to the patient education group had better blood pressure control (138/75 mm Hg) than those in the

58 treated male hypertensive patients with good blood pressure control (139.6/85.7 mm Hg), young blacks,

59 y (1.53, 1.13-2.07; p=0.054), and have their blood pressure controlled (2.06, 1.69-2.50; p<0.0001) th

60 Individually, blood pressure control (57.9%) had the lowest overall at

61 d 82 to a group that received standard care (blood pressure control, a sodium-restricted diet, and an

62 The mechanism(s) underlying blood pressure control across the menstrual cycle in wom

63 s), weight loss (adding 1.6 life-years), and blood pressure control (adding 0.8 life-year).

64 ith HF-preserved EF less frequently achieved blood pressure control (adjusted odds ratio, 0.44 versus

65 Blood pressure control, along with delivery, will be the

66 is not associated with substantial change in blood pressure control, although further research is nee

67 pertension were aware of the diagnosis, with blood pressure control among 32.5% of those being treate

68 s of task-sharing interventions in improving blood pressure control among adults in low-income and mi

69 cing hypertension prevalence, improvement in blood pressure control among people with diagnosed hyper

70 in statistically significant improvements in blood pressure control among rural residents in China.

71 ypertensive medication use and its impact on blood pressure control among US adults with hypertension

72 Antihypertensive medication use and blood pressure control among US adults with hypertension

73 r CRH intensity was associated with improved blood pressure control among veterans with diabetes (79.

74 ed renal function had a beneficial effect on blood pressure control and a nondeleterious effect on re

75 a post hoc analysis of the Effect of Strict Blood Pressure Control and ACE Inhibition on Progression

76 medical therapy as a factor leading to poor blood pressure control and adverse outcomes remains a ke

77 med by local context, substantially improved blood pressure control and cardiovascular disease risk.

78 ction to BP in T2D may contribute to altered blood pressure control and cardiovascular risk in this p

79 Furthermore, myeloid MR is critical for blood pressure control and for hypertrophic and fibrotic

80 rect targets and mechanisms linking FGF21 to blood pressure control and hypertension are still elusiv

81 udy identifies a new role for vascular MR in blood pressure control and in vascular aging and support

82 t protocols including intensive glycemic and blood pressure control and laser photocoagulation for ne

83 ions, in addition to meticulous attention to blood pressure control and lifestyle changes, have the p

84 egarding the importance of blood glucose and blood pressure control and may motivate patients to achi

85 The C1 neurons are a nodal point for blood pressure control and other autonomic responses.

86 stained-release- or atenolol-based strategy; blood pressure control and outcomes were equivalent.

87 describe the role of pressure natriuresis in blood pressure control and outline the cascade of biophy

88 a complex but important factor in achieving blood pressure control and reducing adverse cardiovascul

89 ssociations between key measures of systolic blood pressure control and safety and efficacy outcomes.

90 procedures sometimes offer major benefits in blood pressure control and stabilization of renal functi

91 tional basis for the effects of estrogens on blood pressure control and suggest a mechanism for the m

92 LA dilatation may be mediated by blood pressure control and the development of visceral a

93 ion to improve both medication adherence and blood pressure control and to reduce cardiovascular even

94 ffers multiple benefits, including sustained blood pressure control and tumor response in PPGL patien

95 rtensive patients need two or more drugs for blood-pressure control and concomitant statin treatment

96 latory diastolic blood pressures, along with blood-pressure control and response rates, were apparent

97 terol control, 1 in 3 persons still has poor blood pressure control, and 1 in 5 persons still has poo

98 entive measures including smoking cessation, blood pressure control, and lipid management.

99 tosis, vascular function, matrix remodeling, blood pressure control, and metabolism.

100 inhibitors and ARBs have similar effects on blood pressure control, and that ACE inhibitors have hig

101 9.28%; 95% CI, 8.22%-10.32%; P < .001), and blood pressure control (APD, 3.55%; 95% CI, 3.25%-3.85%;

102 ange between the proportion of patients with blood pressure control/appropriate response for individu

103 directed toward earlier and more aggressive blood pressure control are likely to offer the greatest

104 Strategies used system-wide included blood pressure control as a performance measure, automat

105 e hoping that it would translate into better blood pressure control as well as incremental nephroprot

106 are, was noninferior with regard to systolic blood pressure control at 12 weeks.

107 procedural complications within 30 days and blood pressure control at 6 and 12 months.

108 The primary outcome was blood pressure control at 6 months.

109 We measured blood pressure control at the index visit, overall good

110 ypertension, chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with plac

111 xide release, whereas for the same degree of blood pressure control, atenolol/bendrofluazide had no e

112 heral vascular disease associated with tight blood-pressure control became significant (P=0.02).

113 nts receiving antihypertensive therapy (with blood pressure controlled below target levels) had reduc

114 additional meaningful barriers to achieving blood pressure control beyond access to the monitor itse

115 he association between adherence and TI with blood pressure control (BP </= 140/90 at the clinic visi

116 ccurred in diagnosis, treatment and adequate blood pressure control (BP below 140/90 mmHg) since 2001

117 as effective in improving both adherence and blood pressure control, but it did not appear to improve

118 tics that could inform strategies to improve blood pressure control by decreasing untreated hypertens

119 tihypertensive drug utilization patterns and blood pressure control by insurance status, age, sex, an

120 ic hypertension (after an initial attempt at blood pressure control by weight reduction, if indicated

121 High rates of blood pressure control can be achieved in all age and et

122 tegration of vestibular system pathways with blood pressure control centers in the ventrolateral medu

123 for aspirin or antithrombotic prescription, blood pressure control, cholesterol control, and smoking

124 r risk management in other fields, including blood pressure control, cholesterol management and antit

125 S" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smok

126 scular disease, including lifestyle factors, blood pressure control, cholesterol-lowering, antithromb

127 rger reductions in blood pressure and better blood pressure control compared with patients who receiv

128 vention including patient education improved blood pressure control compared with provider education

129 sure, we found a small reduction in systolic blood pressure control compared with usual care at 12 mo

130 y controlled hypertension resulted in better blood pressure control compared with usual care.

131 t the importance of dietary sodium intake in blood pressure control, consideration of the most recent

132 ose treated, 52.5% (95% CI, 51.7%-53.4%) had blood pressure control (corresponding to 8.5% [95% CI, 8

133 s from 1999 to the early 2010s, glycemic and blood-pressure control declined in adult NHANES particip

134 The primary outcome was blood pressure control (defined as 120-150 mm Hg systoli

135 Similarly, a strategy of intensive blood pressure control did not result in a significant c

136 First-line treatment includes blood pressure control, dietary and weight management, a

137 ly, the proportion of women meeting practice blood pressure control (difference, -1.80% [95% CI, -2.3

138 sk factors for bleeding should be addressed (blood pressure control, discontinuing unnecessary medica

139 Blood pressure control disparities from 2008 through 201

140 tarling mechanism contributes to compromised blood pressure control during simulated haemorrhage in h

141 r disease, achieved with the use of improved blood-pressure control during the trial, would be sustai

142 ion, skeletal muscle pump was found to drive blood pressure control (EMG --> SBP) as well as control

143 Blood pressure control, especially with medications that

144 ncontrolled blood pressure resulted in >=80% blood pressure control, even when the return visit inter

145 east 28 weeks; they required pharmacological blood pressure control for severe hypertension (systolic

146 of intraventricular hemorrhage, and adequate blood pressure control for the optimization of cerebral

147 ngs for redefinition of future management of blood-pressure control for individuals at high risk of s

148 Achieving the Million Hearts blood pressure control goal by 2022 will require simulta

149 earts initiative includes an ambitious >=80% blood pressure control goal in US adults with hypertensi

150 and 2811 (7.1%) participants in the standard blood pressure control group (hazard ratio 0.76, 95% cre

151 in 2158 (5.3%) participants in the intensive blood pressure control group and 2811 (7.1%) participant

152 l lateral PBN (LPBN) relative to surgery and blood pressure control groups.

153 In overall analyses, intensive blood-pressure control had no effect on kidney disease p

154 Patients randomized to placebo (moderate blood pressure control) had a mean blood pressure of 137

155 Blood pressure control has a pivotal role in reducing th

156 Intensive glycemic and blood pressure control has been shown to delay both the

157 An essential link between the kidney and blood pressure control has long been known.

158 Strategies to improve blood pressure control have been implemented in the Unit

159 orms (1)O(2) and whether this contributes to blood pressure control have remained unknown.

160 Blood pressure control improved significantly more in ab

161 t of this clinical problem, and they achieve blood pressure control in 65% of patients.

162 surgery represents an effective strategy for blood pressure control in a broad population of patients

163 on the contextual red flag, such as improved blood pressure control in a patient presenting with hype

164 there are cardiovascular benefits other than blood pressure control in blocking the renin system rema

165 association with use of these medicines and blood pressure control in countries at varying levels of

166 The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial is a pro

167 The Appropriate Blood Pressure Control in Diabetes study followed 950 su

168 ports its role as a polygenic determinant of blood pressure control in humans, and results obtained f

169 ic baroreceptor afferents act as targets for blood pressure control in hypertension.

170 Yet, blood pressure control in Nepal is inadequate, which is

171 important opportunity for further improving blood pressure control in our society.

172 f ischemic events, but the role of intensive blood pressure control in PAD has not been established.

173 ed statistically significant improvements in blood pressure control in patients with diabetes balance

174 [95% CI, 5.2 to 26.3 percentage points]) and blood pressure control in patients with hypertension (im

175 RCTs showed no significant benefit of RDN on blood pressure control in patients with resistant hypert

176 eplerenone and spironolactone, in improving blood pressure control in patients with resistant hypert

177 ommendations issued by scientific societies, blood pressure control in RTRs is far from the recommend

178 ch is believed to play an important role for blood pressure control in the adult.

179 p; the time-to-event experience of achieving blood pressure control in the intervention versus contro

180 l 3 management processes would achieve 78.1% blood pressure control in the overall US population with

181 s for regulation of catecholamine action and blood pressure control in this widely studied model of h

182 ement process values needed to achieve >=80% blood pressure control in US adults.

183 GI-alpha oxidation in the EDHF mechanism and blood pressure control in vivo, we generated a knock-in

184 regulatory systems that are associated with blood pressure control in women.

185 ther vasopressors may contribute to improved blood-pressure control in CAPD in contrast to hemodialys

186 ms of Na-K-ATPase inhibitors might relate to blood-pressure control in hemodialysis (N = six ultrafil

187 findings emphasise the importance of prompt blood-pressure control in hypertensive patients at high

188 py with an ACE inhibitor was associated with blood-pressure control in most patients with ADPKD and s

189 ere may be differential effects of intensive blood-pressure control in patients with and those withou

190 Early improvement in blood-pressure control in patients with both type 2 diab

191 d to be cost-effective strategies to improve blood-pressure control in rural Kenya.

192 combination that is currently available for blood-pressure control in these patients has not been es

193 Blood pressure control increased an absolute 4.6% (95% C

194 adherence and TI, the odds (OR) of achieving blood pressure control increased by 28% and 55%, respect

195 Compared with standard blood pressure control, intensive blood pressure control

196 Compared with standard blood pressure control, intensive blood pressure control

197 Inadequate blood pressure control is a persistent gap in quality ca

198 Continued blood pressure control is necessary to maintain benefici

199 Although intensive blood pressure control is recommended by major guideline

200 A key factor contributing to poor blood pressure control is suboptimal adherence to prescr

201 assist device support yet their relation to blood pressure control is underexplored.

202 The PCORnet Blood Pressure Control Laboratory is a platform designed

203 The PCORnet Blood Pressure Control Laboratory is designed to be a re

204 s, angiotensin-converting enzyme inhibitors, blood pressure control, lipid control, diabetic glycemic

205 preventive measures (eg, smoking cessation, blood pressure control, lipid management) and viremic co

206 reventive measures (e.g., smoking cessation, blood pressure control, lipid management) and viremic co

207 Blood pressure control, lipid-lowering therapy, angioten

208 ntemporary approach of antiplatelet therapy, blood pressure control, low-density lipoprotein reductio

209 fference, 10% [95% CI, -2% to 20%]) and home blood pressure control (<130/80 mm Hg) was 62% vs 28% (r

210 in cholesterol <70 mg/dL or statin therapy), blood pressure control (<140 mm Hg systolic, <90 mm Hg d

211 At month 6, clinic blood pressure control (<140/90 mm Hg) was 82% vs 72% (r

212 se) of implantable intracardiac devices, and blood pressure control (<140/90 mm Hg).

213 2018, the percentage of participants in whom blood-pressure control (<140/90 mm Hg) was achieved decr

214 Blood-pressure control (<140/90 mm Hg) was achieved in 5

215 cemic control, avoidance of smoking and good blood pressure control may be helpful in preventing or d

216 Particularly in black women, weight and blood pressure control may be important community health

217 Aggressive blood pressure control may be the most important factor

218 ntrol, smoking cessation and prevention, and blood pressure control may help to reduce the risk of ha

219 se clinics), and more veterans with adequate blood pressure control (mean [SD], 20 582 [12 201] per 1

220 12 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pr

221 measured HbA(1c) <7.0%), (3) proportion with blood pressure control (measured blood pressure <140/90

222 CPAP or no therapy while maintaining usual blood pressure control medication.

223 characteristics, simulation models like the Blood Pressure Control Model can help local healthcare s

224 The Blood Pressure Control Model simulates patient blood pre

225 We used the validated Blood Pressure Control Model to quantify changes in clin

226 k of complications, but it appears that good blood-pressure control must be continued if the benefits

227 to prevent the development of HF, especially blood pressure control, must be a priority if mortality

228 patients with hypertension achieve adequate blood pressure control, necessitating novel therapeutic

229 2% to 9.7%], P = .001 for interaction term), blood pressure control (no comorbidities: 9.7% vs 4.3%,

230 e effect of the procedure on renal function, blood pressure control, number of antihypertensive medic

231 f patients enrolled, number treated and with blood pressure controlled, number who missed a scheduled

232 ifferences between fatty acid metabolism and blood pressure control of humans and laboratory animals,

233 Patients with adequate blood pressure control on captopril, hydrochlorothiazide

234 of intensive glycemic control and intensive blood pressure control on the risk of incident QT prolon

235 Blood pressure control optimization is immediate and per

236 ible without significant changes in systolic blood pressure control or adverse events during 12-week

237 or combined incentives, resulted in greater blood pressure control or appropriate response to uncont

238 he change in individuals' likelihood of poor blood pressure control or depressive symptoms, and a sma

239 A) and stenting indicate that improvement in blood pressure control or renal function is not a predic

240 ess than 9.0% (OR, 0.96 [95% CI, 0.74-1.2]); blood pressure control (OR, 0.99 [95% CI, 0.69-1.4]); LD

241 iated with a 25% increased odds of achieving blood pressure control (OR, 1.24; 95% CI, 1.21-1.27).

242 y of DN resulting from improved glycemia and blood pressure control, or whether there were overestima

243 study was designed to assess improvement in blood pressure control over a 10-year period in a large

244 ight loss, smoking cessation, and aggressive blood pressure control, particularly in African-American

245 renal dysfunction could beneficially affect blood pressure control, preserve or prevent deterioratio

246 In this simulation study, intensive systolic blood-pressure control prevented cardiovascular disease

247 h standard blood pressure control, intensive blood pressure control provides a net benefit between th

248 ge point (95% CI -0.7 to 9.5) improvement in blood pressure control rate (69.0% (3415/4952) v 64.6% (

249 Clinic blood pressure control rate below 140/90 mm Hg at week 1

250 We compared blood pressure control rates (using the Seventh Joint Na

251 In contrast, blood pressure control rates among patients with hyperte

252 Blood pressure control rates improved from 45.7% in Sept

253 nts with hypertension to tight or less-tight blood-pressure control regimens.

254 Blood pressure control remains suboptimal worldwide amon

255 ed with 55% and 26% increased likelihoods of blood pressure control, respectively.

256 Yet few trials have tested whether intensive blood-pressure control retards the progression of chroni

257 Blood pressure control, reversal of associated coagulopa

258 lic acidosis and anemia, achieving excellent blood pressure control, reversing cardiovascular complic

259 As compared with standard blood-pressure control, rigorous blood-pressure control

260 ts, Mr R faces several barriers to effective blood pressure control: societal, health system, individ

261 ed established lifestyle recommendations for blood pressure control (sodium reduction, weight loss, a

262 ); however, good glycemic control and strict blood pressure control statistics, were much way behind

263 Change in blood pressure control status (<140 mm Hg) was 69% in th

264 There is a pressing need for blood pressure-control strategies with improved efficacy

265 mphocytes in peripheral tissues important in blood pressure control, such as the kidney and vasculatu

266 wide-association studies broaden our view of blood pressure control, suggesting that renal sympatheti

267 Reaching blood pressure control (systolic <140 mm Hg) by 6 months

268 Blood pressure control (systolic BP <140 mm Hg and diast

269 ular disease who received intensive systolic blood-pressure control (target, <120 mm Hg) had signific

270 iometabolic events and death, independent of blood pressure control, than for patients with essential

271 Thus, with intensive blood pressure control, the risk of an event was not inc

272 Of neural sites participating in blood pressure control, the rostral ventrolateral medull

273 In addition to blood pressure control, therapies targeting load-indepen

274 dial benefits of sacubitril/valsartan beyond blood pressure control, though larger studies are needed

275 intensive glucose lowering as well as strict blood pressure control through blockade of the renin-ang

276 ial cells, consistent with a primary role in blood pressure control through modulation of vascular to

277 drugs are widely available, in many patients blood pressure control to guideline-recommended target v

278 cose cotransporter 2 inhibitor [SGLT2i], and blood pressure control to less than 130/80 mm Hg or less

279 Achievement of blood pressure control to less than 140/90 mm Hg was sim

280 t (OR, 8.22 [95% CI, 7.56-8.94]), and having blood pressure controlled to less than 140/90 mm Hg (OR,

281 factor for stroke, a national guideline for blood-pressure control to reduce the incidence of stroke

282 tatistically significant, ranging from 0.01 (blood pressure control) to -0.21 (cholesterol control in

283 rimary care adults enrolled in the Achieving Blood Pressure Control Together trial between September

284 Patient outcomes (glycemic, cholesterol, and blood pressure control, urgent care visits, emergency de

285 ned to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac m

286 Blood pressure control was assessed using the patient's

287 h standard blood pressure control, intensive blood pressure control was associated with a 1.73% absol

288 Blood pressure control was higher in both age groups wit

289 to 80+/-11 mm Hg, respectively; P<0.05), and blood pressure control was more facile in approximately

290 Blood pressure control was poor in both groups (52% to 5

291 Two-year blood pressure control was similar between groups.

292 th standard blood-pressure control, rigorous blood-pressure control was associated with a slower incr

293 To test this hypothesis and its relevance to blood pressure control, we determined whether RGS2 funct

294 enin ratio (ARR), serum potassium level, and blood pressure control were assessed at 3 months and at

295 Significant positive predictors of adequate blood pressure control were CHD and antihypertensive med

296 vascular mortality and results for intensive blood pressure control were inconsistent.

297 eceiving tight, as compared with less tight, blood-pressure control were not sustained during the pos

298 The benefits of previously improved blood-pressure control were not sustained when between-g

299 affordability to use of these medicines and blood pressure control with multilevel mixed-effects log

300 of patients still do not achieve recommended blood pressure control worldwide.